This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Radiation Therapy  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 134 words of the full text and any section headings.

To the Editor: Dr Regine and colleagues¹ attempted to determine whether the addition of gemcitabine to adjuvant fluorouracil chemoradiation improved survival for patients with resected pancreatic adenocarcinoma. They hypothesized that patients in the control group would have a median survival of 18 months and gemcitabine would increase that to 27 months or more. Patients were stratified by nodal status, tumor diameter, and surgical margin status.

However, the authors did not provide the median survival of all patients in either the control group or the gemcitabine group, only those with pancreatic head tumors. In addition, survival was not presented according to the stratification factors.

Financial Disclosures: None reported.

Disclaimer: The views expressed herein are those of the author and do not necessarily represent the views of the National Institutes of Health or the US government.

Bhadrasain Vikram, MD
vikramb@mail.nih.gov
Clinical Radiation Oncology Branch
National Cancer Institute
Rockville, Maryland

1. Regine WF, Winter KA, Abrams RA; et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. JAMA. 2008;299(9):1019-1026. FREE FULL TEXT

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2008;299(24):2852.

RELATED ARTICLE

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial
William F. Regine, Kathryn A. Winter, Ross A. Abrams, Howard Safran, John P. Hoffman, Andre Konski, Al B. Benson, John S. Macdonald, Mahesh R. Kudrimoti, Mitchel L. Fromm, Michael G. Haddock, Paul Schaefer, Christopher G. Willett, and Tyvin A. Rich
JAMA. 2008;299(9):1019-1026.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Survival for Patients With Pancreatic Cancer After Addition of Gemcitabine to Fluorouracil Chemoradiation
Tetsuji Fujita
JAMA. 2008;299(24):2852.
EXTRACT | FULL TEXT  

Survival for Patients With Pancreatic Cancer After Addition of Gemcitabine to Fluorouracil Chemoradiation—Reply
William F. Regine, Kathryn A. Winter, and Howard Safran
JAMA. 2008;299(24):2852-2853.
EXTRACT | FULL TEXT